Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants
Chachoua I., Pecquet C., El-Khoury M., Nivarthi H., Albu R-I., Marty C., Gryshkova V., Defour J-P., Vertenoeil G., Ngo A., Koay A., Raslova H., Courtoy PJ., Choong ML., Plo I., Vainchenker W., Kralovics R., Constantinescu SN.
Key Points Calreticulin mutants responsible for myeloproliferative neoplasms specifically activate the thrombopoietin receptor and in turn JAK2. Activation of the thrombopoietin receptor requires the glycan binding site and a novel C-terminal tail of the mutant calreticulin.